Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2025

Conditions

Lung Cancer

Interventions

DRUG

Gefitinib

Gefitinib 250 mg/day oral daily

Trial Locations (1)

China-Japan Friendship Hospital, Beijing

All Listed Sponsors

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Chinese PLA General Hospital

OTHER

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY